Deals Analysis

Features

These were the biggest pharmaceutical deals in early 2022

GlobalData tracks the latest acquisitions, mergers, venture financing and asset transactions in the pharmaceutical sector.

Data Journalism Team

Features

Top and emerging locations for M&A deals in the pharmaceutical industry

Features

Inside Philip Morris’ controversial Vectura acquisition

Deals

Science park merger creates UK’s largest life sciences ecosystem

Deals

AZ’s proposed acquisition of rare disease-focused Alexion gets US clearance

Features

Exscientia raises $100m Series C funding to develop fully autonomous drug design

Features

SIRION and Sanofi partner on next-gen AAV gene therapy vectors

Features

Merck-Pandion acquisition: re-balancing immune response to treat autoimmune disease

Features

Veteran investor Dr Robert Glassman talks life sciences, immunotherapy and Umoja

Deals

Targeting immune diseases: Longwood Fund founds ImmuneID with $17m financing

Deals

Precision medicine in AMD: SPAC merger sees Gemini make its public debut

Features

Imcyse closes €21.3m Series B as new partner Pfizer takes equity stake

Features

AbbVie and Caribou team up on next-gen off-the-shelf CAR-T therapies

Features

Q&A with SVB’s Nooman Haque: what does 2021 have in store for healthcare investment?

Features

Q&A with Goodwin’s Andrew Harrow: exploring the pharma deals outlook in 2021

Deals

Horizon acquires Viela for $3bn to drive innovation and long-term growth

Features

TCR-T cell therapies for cancer: TScan raises $100m in Series C round

Features

Bispecific antibodies and cancer: Lilly and Merus team up on T cell engager therapies

Features

Exploring dark antigens: Enara and Boehringer Ingelheim sign oncology partnership

Deals

Phesi and Sensyne to collaborate on synthetic control arms for clinical trials

Features

Disease-cancelling drugs: Immuneering raises $62m in Series B round

Features

Biopharma M&A: EY analysts optimistic for 2021 deals after a mixed 2020

Dashboards

Pharma November deals snapshot